Former President · Allogene Therapeutics, Inc. (ALLO)

Joshua Kazam

FY2018 is the first fiscal year CompBrief holds for Joshua Kazam as a named executive officer of Allogene Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2018

$3,592,474

Salary $0Stock awards $3,592,474

2nd of 4 named executive officers at Allogene Therapeutics by FY2018 total.

4 named officers on file for Allogene Therapeutics, FY2018

Joshua Kazam’s pay file — $29

  • 1 fiscal year of pay, line by line
  • ALLO’s disclosed peer group of 20 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Allogene Therapeutics’s whole pay program stands against its peers

  • Allogene Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ALLO→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 24, 2019 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Joshua Kazam’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Joshua Kazam compensation by year

Allogene Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as Allogene Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2018
Salary$0
Bonus$0
Stock awards$3,592,474
Option awards$0
Non-equity incentive$0
Pension and deferred compensation$0
All other$0
Total$3,592,474

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Allogene Therapeutics, Inc. DEF 14A filed April 24, 2019, accession 0001193125-19-115774, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Allogene Therapeutics, Inc. filed document, accession 0001193125-19-115774. Every figure is read from that document and cited to the page and table it appears in. Filed April 24, 2019.

Equity holdings

unvested awards at FY2018 year-end
TypeUnvested unitsValue at year-endExercise price
RSU1,028,951$27,709,650—

Per the Outstanding Equity Awards at Fiscal Year-End table in Allogene Therapeutics, Inc.'s FY2018 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

8 Form 4 lines since the FY2018 proxy (filed April 24, 2019)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-06-18Exercise or conversion derivative—47,700$0.000
2026-06-18Grant or award derivative—95,400$0.0095,400
2026-06-18Exercise or conversion—47,700$0.00398,463
2025-12-18Exercise or conversion—47,700$0.00350,763
2025-12-18Exercise or conversion derivative—47,700$0.0047,700
2025-06-18Grant or award derivative—94,500$0.0094,500
2024-06-05Grant or award derivative—191,082$0.00191,082
2023-06-13Grant or award derivative—116,120$0.00116,120

The 8 most recent of 8 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Allogene Therapeutics’s named executive officers, FY2018

as the company reported each
Named executive officerRoleFY2018 total
David ChangPresident and Chief Executive Officer$12,848,537
Joshua Kazam · this pageFormer President$3,592,474
Eric SchmidtChief Financial Officer$2,588,989
Alison MooreChief Technical Officer$1,836,614

Board service

Allogene Therapeutics board · FY2021–FY2025
Director compensation in US dollars, as Allogene Therapeutics reports it. Most recent year first; a dash means the company reported no figure in that column.
Fiscal yearCash feesStock awardsOption awardsOtherTotal
FY2025$47,000$123,066$0$0$170,066
FY2024$54,000$0$298,650—$366,650
FY2023$50,500$0$423,993$210,000$684,493
FY2022$54,000$424,992$0$657,000$1,135,992
FY2021$54,000$424,988$0$603,160$1,082,148

Each year as the company reported it in Allogene Therapeutics's director compensation table. Totals are the company's own disclosed totals.

How this board is paid

Company policy: Allogene Therapeutics pays directors a $40,000 cash retainer and $300,000 in RSUs/Options. As stated in Allogene Therapeutics's FY2025 proxy.

Committees

International and Business Development Oversight

The full Allogene Therapeutics compensation record

free company brief

This page is one person within Allogene Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Allogene Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Allogene Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Joshua Kazam's compensation dossier · One-time report. No refunds.